[Application progress of liquid chromatography tandem mass spectrometry in precision medicine].

Liquid chromatography tandem mass spectrometry (LC-MS/MS) is an analytical method that combines high separation of liquid chromatography with high selectivity and sensitivity of mass spectrometry. In recent years, LC-MS/MS has been widely used in clinical practice, including screening of inherited disorders, determination of endogenous compounds and analysis of biomarkers. LC-MS/MS is of great value to the precision prevention, diagnosis and treatment of some diseases due to its accurate data. This article not only illustrates the advantages of LC-MS/MS in precision medicine, but also prospects the future trend of LC-MS/MS in clinical practice, which expects to promote the development of clinical LC-MS/MS in the prevention, diagnosis and treatment of diseases.

[Relative bioavailability of effervescent tablet of potassium chloride in healthy volunteers].

AIM: To probe the approach by which the pharmacokinetics and relative bioavailability of endogenous medicinal substances can be studied. METHODS: A randomized three-crossover study was performed in 18 healthy male volunteers. In two of the three study periods, a single 2 g dose of either effervescent tablet or common tablet of potassium chloride was administered; whereas in one of three periods no drug treatment was given to allow the nondrug-related (endogenous) potassium in urine to be determined. In each period the urine samples were collected at the following intervals: 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-24, 24-48 h after dose. Urine potassium was determined and the cumulative urine potassium-time data were fitted to a one-compartment model with first-order absorption. Bioavailability was represented by cumulative amount of potassium excreted in urine during 48 hours after drug administration and the bioequivalence of the two formulations was evaluated by analysis of variance and two one-sided t-test. RESULTS: The pharmacokinetic parameters were as follows: effervescent tablet T1/2 ke = (6 +/- 5) h, T1/2 ka = (0.08 +/- 0.08) h, ku = (0.09 +/- 0.04) h-1, Xmax/f = (18 +/- 8) mmol; common tablet T1/2 ke = (8 +/- 5) h, T1/2 ka = (0.11 +/- 0.11) h, ku = (0.07 +/- 0.04) h-1, Xmax/f = (18 +/- 8) mmol. Relative bioavailability of effervescent tablet was 97.5% +/- 15.2% compared with common tablet. CONCLUSION: The two formulations were of bioequivalence. The methods used in this study might be applicable to other similar studies involving endogenous medicinal substances.